Related Experiment Video
Updated: Aug 11, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
PCV chemotherapy for recurrent glioblastoma
F Schmidt1, J Fischer, U Herrlinger
1Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Medical School, Tuebingen, Germany. friederike.schmidt@uni-tuebingen.de
Neurology
|March 1, 2006
Summary
The procarbazine, CCNU (lomustine), and vincristine chemotherapy regimen showed limited efficacy in recurrent glioblastoma patients, with mild nonhematologic toxicity but significant hematologic side effects.
Area of Science:
- Neuro-oncology
- Clinical Pharmacology
- Cancer Therapeutics
Background:
- Recurrent glioblastoma presents a significant therapeutic challenge.
- Limited effective treatment options exist for patients with recurrent disease.
Purpose of the Study:
- To evaluate the efficacy and toxicity of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) in patients with recurrent glioblastoma.
Main Methods:
- A cohort of 86 patients with recurrent glioblastoma received the PCV chemotherapy regimen.
- Patient responses, progression-free survival (PFS), and toxicity were assessed.
Main Results:
- The PCV regimen resulted in three partial responses, with no complete responses observed.
- Median progression-free survival was 17.1 weeks, and 6-month PFS was 38.4%.
- World Health Organization grade III/IV hematologic toxicity occurred in 25.6% of patients, while nonhematologic toxicity was mild.
Conclusions:
- The PCV regimen demonstrated limited clinical activity in recurrent glioblastoma.
- Hematologic toxicity is a notable concern with this treatment combination.
